Tilray Brands, Inc. TLRY

Alternate Symbol(s): T.TLRY

Healthcare Cannabis

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. The Distribution business segment is focused on the purchase and resale of pharmaceutical products to customers. The Beverage alcohol business segment is engaged in the production, marketing and sale of beverage and beverage alcohol products. The Wellness business segment includes hemp foods and hemp-based cannabidiol (CBD) consumer products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Bake Sale, XMG, Mollo, and others.

NDAQ:TLRY - Post by User

Tilray Brands, Inc. > Tilray Brands German Market by

<< Previous

Bullboard Posts

Next >>

Comment by DaveInCalgaryon Feb 18, 2024 4:09pm

88 Views

Post# 35886892

RE:RE:RE:RE:RE:Tilray Brands German Market by

Ventura what this fellow is trying to mislead others is by suggesting the German Medical Cannabis supply and distribution is going to be wide open. The Wild West.

The Canabis Act was passed Aug 16, 2023.
These questions were asked and published after law passed from the CanG law:

Medical cannabis
41. Will Medical Cannabis still be available in pharmacies with a prescription?

Yes. Medical cannabis should be legally clearly separated from cannabis for non-medical purposes. Medical cannabis is therefore not regulated in the Cannabis Act, but in a separate Medical Cannabis Act. The content of the existing regulations on medical cannabis remains essentially unchanged. Medical cannabis may continue to be prescribed as a medicine in accordance with the applicable social law requirements. However, a prescription for a special narcotic prescription will no longer be necessary in the future. A regular recipe is sufficient here.

42. Does the law now allow any company to grow medical cannabis?
No. The cultivation of cannabis continues to be carried out by companies that were selected in a Europe-wide tender process and commissioned by the Cannabis Agency at the Federal Institute for Drugs and Medical Devices. This cannabis is grown exclusively for medical purposes in accordance with pharmaceutical quality requirements. The prescription requirement remains.

https://www.bundesgesundheitsministerium.de/themen/cannabis/faq-cannabisgesetz-entwurf.html

Aphria/Tilray, Aurora & Demecan have the most to gain.
Aphria growing Medical Cannabis since July 2021 from new
'In Country' facility.

From other reports (once existing contracts expire, after 5 years)

"If sufficient medicinal cannabis can be produced in Germany domestically, this should have a direct impact on the imports to be reported annually to the INCB in accordance with the rules of the Single Convention. Anyone who still wants to sell medicinal cannabis in Germany may also have to produce it in Germany

Having a production site in Germany therefore seems to be becoming much more attractive, especially with regard to the model projects that are still to come. It remains exciting!"

https://businessofcannabis.com/whats-in-store-for-the-european-cannabis-in-2024-part-1/

For future Rec & expanded production, Germany will certainly require 'In Country' grow facilities meeting Medical Cannabis standards.